potential. We agree that cultural change is a major factor in achieving the promise of both personalized care planning and person-centered primary care.

**Samuel T. Edwards, MD, MPH**

**David A. Dorr, MD, MS**

**Bruce E. Landon, MD, MBA, MSc**

**Author Affiliations:** Section of General Internal Medicine, Veterans Affairs Portland Health Care System, Portland, Oregon (Edwards); Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland (Dorr); Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts (Landon).

**Corresponding Author:** Samuel T. Edwards, MD, MPH, Section of General Internal Medicine, Veterans Affairs Portland Health Care System, 3710 SW US Veterans Hospital Rd (R2D199), Portland, OR 97239

(samuel.edwards@va.gov).

**Conflict of Interest Disclosures:** The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Landon reported receiving travel support from the Meyers-JDC Brookdale Institute and EagleDream Health; receiving personal fees from Research Triangle Institute International, UpToDate, Evidera, the American Board of Internal Medicine, and Friedman Healthcare Consulting; and serving as a member of the Newton, Massachusetts, Healthcare Advisory Committee. No other disclosures were reported.


**Persistence of Penicillin Allergy**

**To the Editor** The JAMA Insights article on penicillin allergy stated that many children and adults are erroneously labeled as penicillin allergic. However, the title could falsely suggest that only a very small proportion of these patients had ever experienced a true IgE-mediated reaction to penicillins. Dr Sabato and colleagues argue for “thorough evaluation of individual patients” to avert diagnostic error with potentially serious consequences.

**Vito Sabato, MD, PhD**

**Margo Hagedores, MD, PhD**

**Didier Ebo, MD, PhD**

**Author Affiliations:** Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp, Belgium.

**Corresponding Author:** Didier Ebo, MD, PhD, Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium (didier.ebo@uantwerpen.be).

**Conflict of Interest Disclosures:** The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.


**In Reply** Our intended primary message was that following careful specialist evaluation, most individuals thought to be penicillin allergic will have negative skin testing and oral challenge, enabling them to be safely exposed to penicillins in the future without fear of an immediate or life-threatening reaction. A recent study suggests 75% of children clinically diagnosed with penicillin allergy have this documented on their health record by age 3 years. This childhood label of penicillin allergy imparts both an individual and public health burden that typically goes unchallenged into adulthood. One major reason that most patients carrying a diagnosis of penicillin allergy have negative skin testing and oral challenge and demonstrate future tolerance of penicillin is that only a very small proportion of these patients had ever experienced a true IgE-mediated reaction to penicillins.

Dr Sabato and colleagues argue for “thorough evaluation of individual patients.” Penicillin skin testing followed by oral challenge in the history-positive, skin test-negative patient is a safe and effective mechanism to remove the diagnosis of IgE-mediated penicillin allergy in more than 90% of those tested. This approach is the current guideline-based standard of care. Particularly if partnered with antibiotic stewardship programs, this approach could improve antibiotic appropriateness and reduce the risk of adverse public health outcomes such as antibiotic resistance and *Clostridium difficile* infection. However, patients with a history consistent with an IgE-mediated reaction and a reaction within the last 12 months are at risk of a severe allergic reaction on subsequent exposure and should be treated as penicillin allergic.
months define a higher-risk population for a positive skin test, positive oral challenge reaction, or both.\textsuperscript{2,3} Evidence exists for both penicillins and cephalosporins showing that among patients with initial positive skin tests, skin test reactivity is lost over time. These studies, however, are limited by the lack of oral challenge data both at baseline—at the time of positive skin testing and at follow-up when the skin test has become negative.\textsuperscript{4,5} Overall, less than 1% of the population will be advised to avoid penicillin based on both a history consistent with an IgE-mediated reaction and positive penicillin skin testing. We agree that in this select population, long-term studies are warranted to define the safest clinical approaches, as well as the mechanisms and host and ecologic factors that drive sensitization and future loss of reactivity.

Jason A. Trubiano, MBBS
N. Franklin Adkinson, MD
Elizabeth Jane Phillips, MD

Author Affiliations: Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia (Trubiano); John Hopkins Asthma and Allergy Center, Baltimore, Maryland (Adkinson); Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee (Phillips).

Corresponding Author: Elizabeth J. Phillips, MD, Vanderbilt University Medical Center, Oates Institute for Experimental Therapeutics, 1161 21st Ave S, A2200 Medical Center North, Nashville, TN 37232-2582 (elizabeth.j.phillips@vanderbilt.edu).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Trubiano reports receipt of support from a National Health and Medical Research Council of Australia (NHMRC) postgraduate research scholarship. Dr Adkinson reports being a founding partner in AllerQuest. Dr Phillips reports receipt of grants from the NHMRC, National Institutes of Health, and Australian Centre for HIV and Hepatitis Virology Research; personal fees from UpToDate, Biocryst, and Aicuris; and being condirector of IIID Pty Ltd, which holds a patent for HLA-B*57:01 testing for abacavir hypersensitivity.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgment and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.